Skip to main content
Caplight Logo









Psilera

Psilera

Private
Tampa, FloridaHealthcare & Life Scienceshttps://www.psilera.com/

Last Round

Seed

May 28, 2026

Total Funding Raised

$13.5M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Psilera is a biotechnology company that develops groundbreaking first-in-class treatments for neurological disorders by creating a new class of next-generation neuroplastogens.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Mental Health, Medical AI

Business Model

B2B

Customer Profile

Data as a Service, Services & Consulting

AI Layer

Infrastructure

Keywords

drug discoverycomputational drug discoverybiotechnologyAI drug discoverycheminformaticsneurological therapeuticsvirtual screeningdrug developmentin silico drug discoverypreclinical researchpsychiatric therapeuticsmolecule optimizationbiotech platformpharma R&DAI-native biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Psilera Comparables

Compare Psilera with similar companies based on industry and business-model similarity.

Psilera comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Xylo Bio
79%
Exin Therapeutics
79%
VCENNA
79%

Psilera Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedMay 28, 2026
GrantOct 2, 2025
GrantSep 5, 2024
SeedJul 1, 2021

Key People

Founding team and executive leadership

Jackie von Salm

Co-Founder Chief Scientific Officer

Founding Team

Chris Witowski

Co-Founder and CEO

Founding Team

Psilera Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 22, 2026

    Monthly visitors increased 87% MoM.

  • May 28, 2026

    $9M raised in Seed funding.

Recent news

Latest coverage and updates

  • hiresAug 27, 2026

    Psilera hired Allyson Gage as Vice President, Clinical Development on Aug 27th '26.

  • launchesJun 23, 2026

    Psilera Inc. launched novel synthetic platform on Jun 23rd '26.

Psilera Filings

Explore SEC and related filing metadata, where available.

Psilera filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Psilera's valuation, stock price, and market status.

Is Psilera a public or private company?

Psilera is a private company.

What is the current stock price of Psilera?

Psilera is a private company with no public stock price. No recent secondary market data is available.

How much is Psilera worth (valuation)?

Valuation information for Psilera is not publicly available.

Can I buy Psilera stock?

Psilera shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Psilera's last funding round?

Psilera's most recent funding round was Seed on May 28, 2026.

Who are the main investors in Psilera?

Key investors in Psilera include Iter Investments.

Will Psilera IPO soon?

No public IPO plans have been announced for Psilera.

How can I track Psilera secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Psilera's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersTampa, Florida
Employee Range10
Year Founded2019
Last FundingMay 28, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?